This HTML5 document contains 48 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
foafhttp://xmlns.com/foaf/0.1/
n15http://linked.opendata.cz/resource/drugbank/drug/DB09019/identifier/chebi/
n4http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
n10http://linked.opendata.cz/resource/drugbank/drug/DB09019/identifier/wikipedia/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n5http://linked.opendata.cz/ontology/drugbank/
owlhttp://www.w3.org/2002/07/owl#
n6http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n12http://linked.opendata.cz/resource/drugbank/drug/DB09019/identifier/kegg-drug/
n11http://linked.opendata.cz/resource/drugbank/drug/DB09019/identifier/drugbank/
n8http://www.drugs.com/international/
n14http://linked.opendata.cz/resource/atc/
n13http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB09019
rdf:type
n5:Drug
n5:description
Bromhexine is an expectorant/mucolytic agent. Bromhexine is not available in the United States. It is marketed under the trade name Bisolvon(R) in Germany, England, Belgium, France, Italy, Netherlands, Norway, Sweden, Australia, and South Africa.
n5:group
approved
owl:sameAs
n4:DB09019
dcterms:title
Bromhexine
adms:identifier
n10:Bromhexine n11:DB09019 n12:D07542 n15:77032
n5:synonym
Bromhexinum 3,5-Dibromo-N(alpha)-cyclohexyl-N(alpha)-methyltoluene-alpha-2-diamine Fluibron Bromexina Tauglicolo Bromhexina N-Cyclohexyl-N-methyl-(2-amino-3,5-dibrombenzyl)amine
n5:salt
n5:synthesisReference
U.S. Patent 3,336,308.
foaf:page
n8:bromhexine.html
n5:IUPAC-Name
n6:271B6550-363D-11E5-9242-09173F13E4C5
n5:InChI
n6:271B6556-363D-11E5-9242-09173F13E4C5
n5:Molecular-Formula
n6:271B6555-363D-11E5-9242-09173F13E4C5
n5:Molecular-Weight
n6:271B6552-363D-11E5-9242-09173F13E4C5
n5:Monoisotopic-Weight
n6:271B6553-363D-11E5-9242-09173F13E4C5
n5:SMILES
n6:271B6554-363D-11E5-9242-09173F13E4C5
n5:Water-Solubility
n6:271B654E-363D-11E5-9242-09173F13E4C5
n5:logP
n6:271B654F-363D-11E5-9242-09173F13E4C5 n6:271B654C-363D-11E5-9242-09173F13E4C5
n5:logS
n6:271B654D-363D-11E5-9242-09173F13E4C5
n13:hasATCCode
n14:R05CB02
n5:H-Bond-Acceptor-Count
n6:271B655C-363D-11E5-9242-09173F13E4C5
n5:H-Bond-Donor-Count
n6:271B655D-363D-11E5-9242-09173F13E4C5
n5:InChIKey
n6:271B6557-363D-11E5-9242-09173F13E4C5
n5:Polar-Surface-Area--PSA-
n6:271B6558-363D-11E5-9242-09173F13E4C5
n5:Polarizability
n6:271B655A-363D-11E5-9242-09173F13E4C5
n5:Refractivity
n6:271B6559-363D-11E5-9242-09173F13E4C5
n5:Rotatable-Bond-Count
n6:271B655B-363D-11E5-9242-09173F13E4C5
n5:casRegistryNumber
3572-43-8
n5:Bioavailability
n6:271B6562-363D-11E5-9242-09173F13E4C5
n5:Ghose-Filter
n6:271B6564-363D-11E5-9242-09173F13E4C5
n5:MDDR-Like-Rule
n6:271B6565-363D-11E5-9242-09173F13E4C5
n5:Melting-Point
n6:271B6566-363D-11E5-9242-09173F13E4C5
n5:Number-of-Rings
n6:271B6561-363D-11E5-9242-09173F13E4C5
n5:Physiological-Charge
n6:271B6560-363D-11E5-9242-09173F13E4C5
n5:Rule-of-Five
n6:271B6563-363D-11E5-9242-09173F13E4C5
n5:Traditional-IUPAC-Name
n6:271B6551-363D-11E5-9242-09173F13E4C5
n5:pKa--strongest-acidic-
n6:271B655E-363D-11E5-9242-09173F13E4C5
n5:pKa--strongest-basic-
n6:271B655F-363D-11E5-9242-09173F13E4C5